[Effect of probucol in improving hepatic steatosis in rats with non-alcoholic steatohepatitis and the mechanism]

Nan Fang Yi Ke Da Xue Xue Bao. 2014 May;34(5):731-5.
[Article in Chinese]

Abstract

Objective: To determine the effects of probucol on serum parameters and liver histopathology in rats with non-alcoholic steatohepatitis (NASH) and explore the mechanisms.

Methods: Forty male Sprague-Dawley rats were randomly assigned into 4 equal groups, namely the normal control group (NC group) with a standard feeding, high-fat diet group (HD group) fed with a high-fat diet, probucol (500 mg/kg daily) control group (NP group) fed with standard diet, and probucol group fed with a high-fat diet (HP group). After 15 weeks of feeding, the rats were euthanized for histopathological inspection of the liver with HE staining and detection of farnesoid X receptor (FXR), SHP and SREBP-1C expressions using semi-quantitative RT-PCR and Western blotting.

Results: After the 15-week feeding, the rats in HP group had significantly lower levels of serum ALT, AST, cholesterol, bile acid, and free fatty acid than those in HD group (P<0.01 or 0.05). Compared with the normal control group, high-fat diet feeding resulted in significantly decreased mRNA and protein levels of FXR and SHP (P<0.05) and significantly increased SREBP-1C level (P<0.05). These high-fat diet-induced gene expression changes were reversed by probucol intervention (P<0.05).

Conclusion: Probucol treatment has beneficial effects on serum parameters, hepatic steatosis, and lobular inflammation in high-fat diet-induced NASH possibly by up-regulating FXR expression.

MeSH terms

  • Animals
  • Anticholesteremic Agents / pharmacology*
  • Diet, High-Fat
  • Disease Models, Animal
  • Male
  • Non-alcoholic Fatty Liver Disease / blood
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Probucol / pharmacology*
  • RNA, Messenger
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Anticholesteremic Agents
  • RNA, Messenger
  • Probucol